"CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including metastatic colorectal cancer (mCRC) and triple-negative breast cancer (TNBC), today announced that Robert E. Hoffman, Chief Financial Officer, will present live at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on September 17th, 2026."
Framing: assertive ·
First seen: 2026-09-15 ·
Last seen: 2026-09-15 ·
Spread: 1 articles
The Aporia